Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.
BACKGROUND
The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC). Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLC patients. Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded. IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections.


RESULTS
A positive IGF1R expression (score > or = 100) was observed in 282 cases (76.4%) and was significantly associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02). No difference in survival was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used (45 versus 55 months, P = 0.36). No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status.


CONCLUSIONS
IGF1R expression does not represent a prognostic factor in resected NSCLC patients. Patients with squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the different sensitivity to anti-IGF1R agents observed in clinical trials.
Cappuzzo
F
F
Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano. Electronic address: federico.cappuzzo@humanitas.it.
Tallini
G
G
Department of Pathology, Ospedale Bellaria, Bologna, Italy.
Finocchiaro
G
G
Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
Wilson
R S
RS
University of Colorado Cancer Center, Aurora, CO, USA.
Ligorio
C
C
Department of Pathology, Ospedale Bellaria, Bologna, Italy.
Giordano
L
L
Statitistic Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
Toschi
L
L
Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
Incarbone
M
M
Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
Cavina
R
R
Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
Terracciano
L
L
Division of Molecular Pathology, University Hospital, Basel, Switzerland.
Roncalli
M
M
Department of Pathology, University of Milan School of Medicine, Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
Alloisio
M
M
Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
Varella-Garcia
M
M
University of Colorado Cancer Center, Aurora, CO, USA.
Franklin
W A
WA
University of Colorado Cancer Center, Aurora, CO, USA.
Santoro
A
A
Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D012189:Retrospective Studies; D015996:Survival Rate; D046888:Tissue Array Analysis; D016896:Treatment Outcome
D017526:Receptor, IGF Type 1